Bio-Techne Corporation and Leica Biosystems are Accelerating Disease Research with RNAscope COVID-19 Probes and the BOND RX

MINNEAPOLIS, August 19, 2020 — Bio-Techne Corporation (NASDAQ:TECH), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*, Leica’s staining platform, for research use only. Researchers now have the ability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.

“The Bio-Techne R&D team quickly developed COVID-19 specific probes when the genetic sequence of this virus was released,” commented Kim Kelderman, President, Diagnostics and Genomics Segment, Bio-Techne Corporation. “We believe RNAscope™ probes will enable researchers to gain a greater understanding of the pathogenesis of this disease. The availability of these probes on the automated Leica Biosystems platform will expediate important discoveries,” Kim added.

The BOND RX* is a flexible, open platform with the capability to run Bio-Techne RNAscope™ (duplex and multiplex) protocols, allowing for boundless innovation.

“We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment to support researchers in addressing the pandemic.”

The RNAscope™ probes are designed to detect SARS-Cov-2 viral RNA, SARS-Cov-2 viral replication sequences, and cellular receptors targeted by the virus, including ACE2 and TMPRSS2.

*For Research Use Only, Not for Use in Clinical Diagnostic Procedure

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions – notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne’s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide.

About Leica Biosystems
Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Leica Biosystems is headquartered in Germany and operates in over 100 countries.

Contact:
David Clair, Senior Director, Investor Relations & Corporate Development
David.Clair@bio-techne.com
646-277-1266

SOURCE Bio-Techne Corporation

‘Building the New Economy’ by MIT Sloan School

‘Building the New Economy’: MIT Sloan School researchers map out a blueprint to help individuals, infrastructure, and institutions withstand crises, from wars to pandemics

New digital technologies can help build resilient systems and empower communities

News provided by MIT Sloan School of Management, May 22, 2020, 07:30 ET

CAMBRIDGE, MA, May 22, 2020 — How can we make our financial system less fragile and more transparent? How can we make our healthcare infrastructure less reactive and more agile? And what can we do to create more robust civic institutions that work for all of us—not just those at the top?

A new book from researchers at the MIT Sloan School of Management provides answers and insights to those pressing questions. The book, Building the New Economy, is edited by Professor Alex “Sandy” Pentland, leader within the Sloan Initiative for Digital Economy and founder of the MIT-wide Connection Science program, Alexander Lipton, former Managing Director of Quantitative Solutions at Bank of America and Connection Science Fellow at MIT, and Thomas Hardjono, CTO of Connection Science and Technical Director of the MIT Trust-Data Consortium.

“With each new crisis, be it war, pandemic, natural disaster, or even the invention of a major technology, there has been a need to reinvent the relationships between individuals, businesses, and governments. The COVID-19 health emergency and ensuing economic turmoil, joined with the tsunami of data and AI technologies—is such a crisis,” says Prof. Pentland. Continue reading